-
Four billion! Yuheng Pharmaceuticals to buy turnover of 1.44 million yuan company
Time of Update: 2021-02-28
On July 10, Yu heng Pharmaceuticals issued a public announcement on the progress of its major asset restructuring, which showed that Yuheng expects to acquire no less than 35% of Tymco Bio for no less than 4 billion yuan in order to gain control of Tyme Bio. The final price is based on audit and evaluation and shall be determined by the two parties in consultation separately.
-
Invest another $2.5 billion! Yang Sen is going to play the next big game in China.
Time of Update: 2021-02-28
This investment was completed by Xi'an Yangsen, a Chinese pharmaceutical unit owned by Johnson and Johnson, to build a new supply chain production base in Xi'an for US$397 million (RMB2.55 billion) and is scheduled to start production in the second half of 2019 as an important physical preparation production center serving China and the Asia-Pacific region as a whole.
-
"Stock speculation" loss of 1.378 billion yuan Shanghai Lais "Blood King" status is difficult to protect
Time of Update: 2021-02-28
On February 22 this year, Shanghai Laix suspended trading on the grounds of restructuring, with a market capitalisation of 97.1 billion yuan, still ranking fourth in the A-share pharmaceutical industry.
According to the 2018 semi-annual report, Shanghai Laix' investment income was RMB1.37 billion and net profit was RMB855 million.
-
Only Hengrui Pharmaceuticals and Kangmei Pharmaceuticals have a market capitalization of 100 billion yuan
Time of Update: 2021-02-27
as of the close of trading on August 23rd, the only pharmaceutical stocks with a market capitalisation of 100 billion were Hengrui Pharmaceuticals and Kangmei Pharmaceuticals, but so far this year, the rise in Pharmaceuticals Mingkangde, Chipo and Zhifei Bio has been staggering.
-
5 billion yuan "white medicine" market pattern changes Hengrui 19K into the big
Time of Update: 2021-02-27
According to the experience after the listing of neulasta, the long-term characteristics of the second generation of white medicine products are very competitive, the current domestic G-CSF sample hospital market sales of 998 million yuan, long-acting drugs only 12.62 percent, so the product long-term replacement short-acting space is equally huge.
-
Kanghong Pharmaceuticals' first-half profit was 310 million yuan, up 33% YoY
Time of Update: 2021-02-27
From January to June, the Company achieved operating income of RMB1.383 billion, up 1.03% YoY, while net income attributable to shareholders of listed companies was RMB310 million, up 33.13% YoY, and basic earnings per share was RMB0.46.
-
Ali Health's net profit increased by 100% and its consumer healthcare business increased significantly
Time of Update: 2021-02-27
Consumer Healthcare's business improved significantly according to the announcement, Ali Health provided users with an average of more than 1 million medical and health services per day through Alipay, Taobao and other platforms, including payment, registration, online health consulting, etc., while revenue from its consumer healthcare business, including vaccines, oral medicine and medical services, grew 125.1% year-on-year.
-
Harpoon's $2 billion acquisition of GNC U.S. agreed
Time of Update: 2021-02-27
After passing the REVIEW of CFIUS, we need to wait for the approval or filing of Heilongjiang National Development and Reform Commission and other regulatory bodies, Ha Pharmaceuticals is not far from
-
Liaoning Chengda Bio to Hong Kong IPO: Gross margin is more than 80%
Time of Update: 2021-02-27
end of 2014, Chengda Bio is listed on the new three boards, is currently an innovative layer of enterprises, the transfer mode is "market transfer." With many enterprises landing on the new three boards after the "zero transaction, no financing" situation is different, into the big creatures many times the daily turnover of more than 10 million yuan, in addition to the success of a new issue, raising a net 266 million yuan.
-
More than 9 months after breaking up with Pfizer, Haizheng Pharmaceuticals has re-emerged out of stock
Time of Update: 2021-02-27
An exclusive letter to experts from a reporter for Securities Daily, a communication note on the temporary tight supply of Rui Yining (hereinafter referred to as the Communication Note), shows that Reynin's semi-finished medicine is manufactured by Pfizer's Puerto Rico plant, which was severely affected by Hurricane Maria and suffered serious damage to production capacity.
-
The signing amount reached 8.3 billion yuan Zhejiang enterprises to import drugs and medical equipment
Time of Update: 2021-02-27
This signing activity is divided into imported drugs, imported medical supplies, imported medical equipment three links, from AstraZeneca, Sanofi and other imported drug suppliers, Johnson and Johnson, Medtron and other imported medical supplies suppliers and GE, Siemens, Philips and other imported imaging equipment suppliers with Zhejiang Province Pharmaceutical Procurement Center (on behalf of users), 12 provincial hospitals and Dean Diagnostics, American Health, Aibo Health, Tongze Group and other four health services signed the intention to purchase enterprises.
-
Fangsheng Pharmaceuticals decided to buy a 51% stake in Sanhua Pharmaceuticals for $10.2 million
Time of Update: 2021-02-27
Fangsheng Pharmaceuticals said that the company intends to obtain a controlling stake in Sanhua Pharmaceuticals through the transfer of equity, is conducive to further enrich the tablet, dispersant dosage form product category, improve comprehensive competitiveness, accelerate the realization of the company's development strategy.
-
160 million! Yiyi Pharmaceutical intends to buy a house from the real controller and other people to build an orthopaedic hospital
Time of Update: 2021-02-27
The real controller and other real estate sales can earn 90 million Yiyi Pharmaceuticals announced that the company's wholly-owned subsidiary Yiyi Investment intends to invest 162 million yuan to buy the controlling shareholder, the actual controller, chairman Du Yuling and concerted actors, company directors, senior management Du Yaqi under the name of six properties.
-
The transformation of the pharmaceutical industry accelerates the multi-point flowering of innovative drug research and development
Time of Update: 2021-02-27
The first impression investors gave investors of the 2009 listing was that the business was sound, and that there had not been a year of declining performance in the nine years since the listing. In 2
-
Johnson and Johnson contributed the most to second-quarter revenue of $20.8 billion in cancer drug sales
Time of Update: 2021-02-27
In the second quarter of 2018, Johnson and Johnson generated revenue of $20.8 billion, of which global cancer drug sales rose 42 percent to $2.46 billion.
-
Black swans have hit the pharmaceutical sector hard, with the market value evaporating by more than $150 billion in four days
Time of Update: 2021-02-27
Changsheng Bio announced on July 18 that it expects to reduce first-half operating income by about 200 million yuan and net profit by about 140 million yuan due to a recall of all batches of freeze-dried human rabies vaccines during the validity period.
-
GSK intends to sell its nutrition business to Lihua for $3 billion
Time of Update: 2021-02-27
GlaxoSmithKline's nutrition business includes the popular Horlicks malt beverage brand in India, and Horlicks' product line, which is sold mainly in Asia, is a nutritional supplement to the children's diet.
-
All over the "ignition" Kangmei Pharmaceuticals half a year to throw more than 3 billion
Time of Update: 2021-02-27
On July 27th, Kangmei Pharmaceuticals, a leading Chinese medicine and beverage company, announced that, after consideration by the first interim shareholders' meeting in 2018, it had approved bills on
-
HNA investment to terminate major asset restructuring core medical assets listed and then stranded
Time of Update: 2021-02-27
On the evening of October 30, HNA Investment announced that the major asset restructuring plan involving 100% equity in Xinsheng Medical and 70% stake in Cihang Hospital had been terminated due to the lack of completion conditions and timing, and faced greater uncertainty.
-
Connbey rebuked the heavy gold stake Jia and biological good chess or stink chess
Time of Update: 2021-02-27
However, jiayu bio in the next 3 years the most likely to be listed clinical Phase III products (GB221, GB242, GB222), similar research and development competition is very fierce, competitors.
addition, another important factor in Connbel's investment in Jia and Bio is the clinical progression of its competitive PD-1 products.
